Clinical Trials Logo

Filter by:
NCT ID: NCT04853927 Withdrawn - Covid19 Clinical Trials

Proxalutamide Treatment for COVID-19 Patients in Intensive Care Unit

Start date: February 8, 2021
Phase: Phase 3
Study type: Interventional

The purpose of this study is to assess the efficacy and safety of Proxalutamide as a treatment for COVID-19 patients in the intensive care unit

NCT ID: NCT04853134 Withdrawn - Covid19 Clinical Trials

Proxalutamide Treatment for COVID-19 Female Outpatients

Start date: November 1, 2020
Phase: Phase 3
Study type: Interventional

This study is intended to explore the possible protective role of anti-androgens in SARS-CoV-2 infection

NCT ID: NCT04831567 Withdrawn - Clinical trials for Neuroendocrine Tumors

Study of MIBG-I131 in Patients With Well Differentiated Neuroendocrine Tumors

MIBNET
Start date: February 4, 2021
Phase: Phase 2
Study type: Interventional

This is a single-arm, unicentric, single-stage, phase 2 clinical study of therapeutic metaiodobenzylguanidine (MIBG) for patients with metastatic well-differentiated neuroendocrine tumors and radiological progression or intolerance after standard lines of treatment and with MIBG positive scan.

NCT ID: NCT04575558 Withdrawn - Sars-CoV2 Clinical Trials

HOPE: A Trial of Hydroxichloroquine Plus Azithromycin in High Risk COVID-19

HOPE_BRAZIL
Start date: June 30, 2020
Phase: Phase 2
Study type: Interventional

Multicenter, double blind, randomized clinical trial for high-risk patients over 18 years of age, symptomatic for COVID-19 infection, without any severity criteria

NCT ID: NCT04505111 Withdrawn - Clinical trials for Enhanced Recovery After Surgery

Prehabilitation Plus ERAS vs ERAS in Gynecological Surgery

Start date: July 23, 2020
Phase: N/A
Study type: Interventional

Prospective, interventionist, controlled and randomized study to test the effectiveness of multimodal prehabilitation protocol in patients who will undergo gynecological surgery.

NCT ID: NCT04499170 Withdrawn - Clinical trials for Balance Disorders Water

Effect of Muscular Energy Technique on Postural Control

Start date: January 2024
Phase: N/A
Study type: Interventional

The research aims to evaluate the immediate effect of the muscle energy technique (TEM) on postural control responses in the elderly and young adults. The sample will be selected for convenience, being participants of both sexes, young and old. Evaluation of postural control through the force platform will be performed during the unipodal and semi-tandem balance tests. The main parameters of postural control will be calculated using the pressure center derivative. After the balance tests, the participants will be submitted to TEM and immediately afterwards reassessed on the force platform.

NCT ID: NCT04495010 Withdrawn - Melanoma Clinical Trials

Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Nivolumab or Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Observation Compared With Adjuvant Nivolumab in Treatment-Naive High-risk Melanoma Participants

CheckMate 7UA
Start date: March 31, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the role of neoadjuvant immunotherapy and to demonstrate high pathologic complete response (pCR) and near pCR rates in melanoma participants with clinically detectable nodal disease and a high risk of recurrence. Neoadjuvant immunotherapy aims to enhance the systemic T-cell response to tumor antigens while detectable tumor is still present, inducing a stronger and broader tumor-specific immune response. Of the neoadjuvant approaches studied within melanoma, the neoadjuvant combination of nivolumab and ipilimumab has demonstrated high pCR and near pCR rates that may translate to prolonged clinical benefit.

NCT ID: NCT04485429 Withdrawn - COVID-19 Clinical Trials

Efficacy Assessment of Methylprednisolone and Heparin in Patients With COVID-19 Pneumonia

Start date: July 20, 2020
Phase: Phase 3
Study type: Interventional

The COVID-19 pandemic has been spreading continuously, and in Brazil, until July 19, 2020, there have been more than 2,000,000 cases with more than 79,000 deaths, with daily increases. The present study proposes to evaluate the efficacy of methylprednisolone and heparin in treatment of patients with COVID-19 pneumonia in a randomized, controlled, 2x2 factorial study.

NCT ID: NCT04458116 Withdrawn - Clinical trials for Coronary Artery Disease

Effects of Curcumin on Markers of Cardiovascular Risk in Patients With CAD

Start date: May 10, 2021
Phase: N/A
Study type: Interventional

- General Objective To evaluate the effects of curcumin supplementation on cardiovascular risk markers, inflammation, oxidative stress and functional capacity in participants with coronary artery disease. Specific Objectives Assess, before and after supplementation with turmeric: - The nutritional status of the participants; - Blood pressure; - Atherogenic risk; - The expression of transcription factors (Nrf2 and NF-kB), antioxidant enzymes (NQO1, HO-1, sirtuin 1 (SIRT-1)), NLPR3 receptor, as well as the levels of inflammatory cytokines (IL-6, tumor necrosis factor-alpha (TNF-α), protein C reactive (PCR), IL-1, IL 18) and vascular cell adhesion protein 1 (VCAM-1) and E-selectin adhesion molecules; - Routine biochemical parameters; - Lipid peroxidation and oxidized LDL; - The 6-minute walk test, the recovery heart rate and the chair lift test; - Modifiable risk factors before and after supplementation; - The comparison of all parameters between groups.

NCT ID: NCT04361461 Withdrawn - Pulmonary Disease Clinical Trials

Use of Hydroxychloroquine Alone or Associated for Inpatients With SARS-CoV2 Virus (COVID-19)

Start date: April 30, 2020
Phase: Phase 3
Study type: Interventional

The Severe Acute Respiratory Syndrome CoronaVirus 2 (SARS-CoV2) has been identified in Wuhan, China, which causes severe pulmonary complications and flu syndrome, which has spread rapidly to all continents. Approximately 25% of hospitalized patients require treatment in intensive care units and 10% require mechanical ventilation. The diagnosis is made by the molecular polymerase chain reaction test. However, diagnostic tests are limited. The clinical care of the patient with COVID-19 is similar to that of patients with severe infectious respiratory complications, consisting of support and oxygen supplementation. Several medications have been tested as remdesivir, a pro-drug nucleoside, which acts by inhibiting viral RNA transcription, although a recently published study has shown no benefit. China recently approved the use of favipiravir, an antiviral used for influenza, as an experimental therapy for COVID-19. Hydroxychloroquine is a drug with great potential treatment, as it can inhibit the pH-dependent steps of replication of various viruses, with a potent effect on SARS-CoV infection and spread. In this way, the present study will evaluate the safety and efficacy of the hydroxychloroquine in patients with symptomatic SARS-Cov2.